Cambridge Healthtech Institute’s Third Annual

Oligonucleotide Discovery and Delivery

Advances in the Development and Delivery of Aptamer, Antisense and RNA Therapeutics

March 26-28, 2018 | Boston Marriott Cambridge | Cambridge, MA

Oligonucleotide-based therapeutics have long been considered as forming the third major drug development platform specifically focused on modulating gene expression by targeting RNA transcripts or the genome itself. A key distinguishing attribute of utilizing nucleic acids as therapeutic agents is their ability to access the “undruggable” space left by small molecules and biologics, allowing drug developers to address disease areas currently with limited or no therapeutics options. However, first- and second-generation molecules exhibiting potency and safety issues have hindered the potential of oligonucleotide therapies dramatically impacting the drug development landscape. Recent advances in nucleic acid medicinal chemistry and delivery have led to the creation of a new generation of oligonucleotide therapies harnessing chemical modifications and conjugations to improve their stability, bioavailability, specificity and potency. These advances, along with a robust development landscape, and several late-stage clinical products poised for approval, have led to a sharp resurgence of interest in the discovery of oligonucleotide-based therapeutics.

Due to the remarkable success of the event, Cambridge Healthtech Institute is delighted to host the Third Annual Oligonucleotide Discovery and Delivery conference, March 26-28, in Cambridge, MA. Join leading oligonucleotide developers and discovery scientists to discuss technological and scientific advances in nucleic acid synthesis, medicinal chemistry and delivery, as well as preclinical and clinical findings.

Who should attend: Executives, Directors, Managers, and Scientists from Pharma, Biotechs, Academia, Government and Healthcare Organizations working in fields such as Oligonucleotide Therapeutics, Immunotherapy, Gene Therapy, Gene Editing and Rare Diseases.

Topics will include, but are not limited to:

Therapeutic Oligonucleotides  Coverage Includes:

  • Antisense single-stranded DNA/RNA oligonucleotides (ASOs)
  • siRNA
  • mRNA
  • ncRNA
  • Aptamers

Part 1: Therapeutic Oligonucleotide Discovery and Development

  • Oligonucleotides for:
    • RNA modulation
    • Antivirals
    • Splicing modulation and exon skipping
    • DNAi
    • Gene editing
      • CRISPR/Cas9
  • Oligonucleotide Synthesis and Chemistry
  • Aptamer Therapeutics
  • Preclinical and Clinical Studies
  • Combination Strategies

Part 2: Delivery

  • Chemical Modifications and Conjugation
    • Improving stability, bioavailability, specificity and potency
  • Improved Oligonucleotide Delivery Methods
    • Nanomaterial-based delivery
    • Non-viral delivery systems
    • Small molecule based delivery
    • Delivery methods for non-hepatic targets
      • Blood-brain barrier
    • Delivery of large nucleic acids

Part 3: Oligonucleotides for Cancer Immunotherapy

  • RNA-Based Vaccines
    • Chemical modifications
    • Immuno-stimulatory adjuvants and co-stimulatory molecules
      • Toll-like receptor agonists
      • Targeting the STING pathway
    • Delivery of RNA vaccines
    • Non-viral delivery strategies
  • Dendritic Cell Vaccines
  • Preclinical and Clinical Combination Studies with Checkpoint Inhibitors
  • Novel Agents Inducing Immune Response
  • Novel Targets for Immunotherapy Development

If you would like to submit a proposal to give a presentation at this meeting, please click here.

The deadline for submission is September 15, 2017.

All proposals are subject to review by the Scientific Advisory Committee to ensure the highest quality of the conference program. Please note that due to limited speaking slots, preference is given to pharmaceutical and biotech companies, regulators and those from academia. Additionally, vendors/consultants who provide products and services to these biopharmaceutical companies are offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

For more details on the conference, please contact:
Kip Harry
Senior Conference Director
Cambridge Healthtech Institute
T: (+1) 781-972-5454
E: kharry@healthtech.com

For partnering and sponsorship information, please contact:
Carolyn Benton
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5412
E: cbenton@healthtech.com